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ABSTRACT  
Objective: Gold nanoparticles (GNPs) have been synthesized and functionalized with chitosan alkanethiol polyethylene glycol as a renal targeting 
ligand (CS-PEG-AlkSH-GNPs) and finally loaded with insulin-like growth factor-I (IGF-I) for selectively and effectively treating acute renal failure. 
Methods: In this study, GNPs were prepared and characterized using transmission electron microscopy, photon correlation spectroscopy and 
inductively coupled plasma (ICP-OES). The surface of the GNPs was further decorated using synthesized CS-PEG-Alk-SH and IGF-I. IGF-I loaded CS-
PEG-ALK-SH-GNP were characterized for their growth factor loading capacity, particle size, zeta potential and dispersion stability. In vitro release 
profile and bioactivity of IGF-I from IGF-I loaded CS-PEG-AlkSH-GNPs were assessed using cell culture technique. Biological distribution, 
pharmacokinetic investigation and toxicity study of IGF-I loaded CS-PEG-AlkSH-GNPs were carried out using experimental animals.  
Results: The size of GNPs was less than 50 nm with a surface charge of about-45 mV. Coating GNPs with CS-PEG-Alk-SH acquired the particles high 
in vitro stability in 5 M NaCl and bovine serum albumin (BSA). The assembly’s bioactivity was tested on cell culture and the released IGF-I was found 
to maintain bioactivity equivalent to its released percentage. When tested on mice, IGF-I loaded CS-PEG-ALK-SH-GNP reached a concentration of 
60% in 6 h time in the kidneys with an elimination half-life higher than that of the control GNPs indicating efficient renal residence and targeting 
processes. The system was proved nontoxic. 
Conclusion: CS-PEG-AlkSH-GNPs could represent an efficient tool for the targeted delivery of growth factors and other biomolecules to the kidneys. 
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About 200 patients per million develop severe acute renal failure 
(ARF) yearly [1, 2], and might require intensive care unit 
hospitalization [3]. Dialytic therapy, although life-saving, is 
expensive, time-consuming and places patients at risk for a diversity 
of complications [4-7]. 
In 1984, autocrine and paracrine growth factors were proposed 
as agents that mediate repair [8, 9-11] in animal models of ARF. 
Three growth factors including epidermal growth factor (EGF), 
insulin-like growth factor I (IGF-I) and hepatocyte growth factor 
(HGF) [12] have been used and their success reported [13, 14], 
of the three growth factors, IGF-I has shown the highest progress 
in ARF curing through multiple mechanisms [15-17], and was the 
first to be used in clinical trials for kidney diseases. Taking into 
consideration that ARF is a highly catabolic state; it was 
observed that unlike EGF or HGF, IGF-I is anabolic even in the 
setting of acute renal injury.  
Recently, GNPs appeared as a type of inorganic metal particles [18, 
19] that are extensively studied in therapeutic contexts and in the 
safe delivery of drugs to a specific site [20, 21]. Nanoparticles (NPs) 
have been shown to reach the systemic circulation after inhalation, 
ingestion or intravenous injection, with further distribution to 
several organs such as liver, spleen, kidneys, brain or heart [22]. 
However, their distribution was found to be clearly affected by their 
particle size [23, 24]. For the biological applications of GNPs in drug 
targeting, two functional components are required; a stealth layer to 
increase their circulation time through avoiding their removal by the 
reticuloendothelial system [25] and a conjugated targeting moiety 
for targeting a specific receptor and enhancing the mechanism of 
cellular uptake [26]. Polyethylene glycol (PEG), whose hydrophilic 
characteristics ensure that the coated particles would have a high 
degree of biocompatibility, affinity for cell membranes and in turn 
increased cellular uptake [27]. In addition, it is expected to prevent 
the aggregation of the GNPs in environments of high ionic strength 
and supports a longer circulation of the particles was used as the 
stealth layer, in addition, it was used as a platform to which a renal 
targeting ligand can be attached [28]. Many authors [29, 30], studied 
the effect of deacetylation degree of chitosan on renal distribution. 
The results indicated that low molecular weight chitosan (LMWC) is 
specifically taken up by renal tubular cells via a megalin-dependent 
endocytotic pathway and is cleared from the kidneys more rapidly 
[31-33]. The main aim of the present work was to test the efficacy of 
IGF-I loaded CS-PEG-ALK-SH-GNP as a possible new selective and 
effective platform for the treatment of renal failure.  
MATERIALS AND METHODS 
Materials 
Tetrachloroauric acid (HAuCl4), polyethylene glycol 4000 (PEG 
4000), polyethylene glycol 2000 (PEG 2000), Dichloromethane, 
Diethyl ether, Tosyl Chloride, Silver Oxide, Toluene, 11-
Bromoundecene, Thioacetic acid, Sodium azide NaN3, Triphenyl-
phosphine, low molecular weight chitosan, N,N'-Dicyclohexyl-
carbodiimide (DCC), N-hydroxysuccinimide (NHS), and insulin-like 
growth factor (IGF) were purchased from Sigma-Aldrich, USA. Other 
chemicals were of analytical grade  
Methods 
Synthesis of amino poly-(ethylene glycol)-undecyl mercaptane 
(NH2PEG2000C11H22
The synthesis of amino poly (ethylene glycol) undecyl mercaptane 
was carried out in two steps as reported in the literature [34, 35]. 
Briefly, monotosytated PEG 2000 was prepared by reacting 
dihydroxy poly (ethylene glycol) with toluenesulfonyl chloride in the 
presence of silver oxide and potassium iodide as shown in fig. 1a. 
This was followed by the reaction of monoprotected poly (ethylene 
glycol) with 11 bromroundecene, and the reaction was completed as 
described in fig. 1b [31]. 
SH) as nanoparticles stabilizing and 
functionalizing agent 
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Fig. 1a: Synthesis of mono-protected poly (ethylene glycol), 1b: Synthesis of amino poly (ethylene glycol) undecyl mercaptane, 1c: 
Synthesis of low molecular weight chitosan and conjugation to amino polyethylene glycol undecyl mercaptane 
 
Synthesis and characterization of low molecular weight 
acetylated chitosan renal targeting ligand 
Chitosan-6-carboxylic acid as a new renal targeting ligand has been 
synthesized by selective oxidation of one HOCH2-group to COOH 
according to fig. 1c. The characterization of the prepared renal 
targeting ligand was carried out using 1
Conjugation of the synthesized polymer with the renal targeting 
ligand (chitosan)  
H-NMR spectroscopy and FT-
IR [36, 37].  
Amino polyethylene glycol undecyl mercaptane (NH2-PEG-AlkSH) 
polymer was conjugated with the low molecular weight chitosan 
through reacting the amine group (NH2
Chitosan conjugated polyethylene glycolalkanethiol CS-PEG-AlkSH 
(fig. 1c, compound 2) was prepared by dissolving Chitosan (0.5 
mmol) in dry dimethylformamide DMF (15 ml) then triethylamine 
(2.5 ml), NHS (115 mg, 1 mmol) and DCC (124 mg, 1.2 mmol) were 
added and the reaction mixture was stirred at room temperature for 
12 h. This step aimed at activating the carboxyl group of chitosan. 
After that, NH
) of the amino polyethylene 
glycol undecyl mercaptane with the carboxyl group (COOH) of the 
prepared renal targeting ligand; chitozan-6-carboxylic acid; 





























































-PEG-AlkSH (1.0 gm, 0.5 mmol) was added and the 
whole reaction mixture was stirred overnight at room temperature. 
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At the end of the reaction, filtration was carried out (to remove 
dicyclohexylurea), and DMF was evaporated under vacuum till 
dryness. The crude product was dissolved in methylene chloride and 
precipitated by dropwise addition to an ice cooled ether. The desired 
product was collected by filtration. The produced compound 
(polymer conjugated chitosan) was characterized by FT-IR and 1
Characterization of the synthesized polymer  
H-
NMR [36, 38]. 
The synthesized polymers were characterized by 1H-NMR, 13C-NMR. 
For NMR of the polymer, they were dissolved in CDCl3
Preparing gold nanoparticles by the citrate reduction method 
 with tetra-
methyl silane as internal standard and subsequently measured using 
Bruker Avance 400 spectrometer (Bruker Biospin, Rheinstetten, 
Germany). 
Gold nanoparticles were obtained by the reduction of HAuCl4
In this method, the citrate salt acts initially as the reducing agent to 
reduce Au (III) 3+ions to Au (0) and later also functions as 
stabilizing agent by forming a layer of citrate anions on top of the 
nanoparticles’ surface, thus, charging the particles by negative 
charges and inducing enough electrostatic repulsion forces between 
individual particles to keep them uniformly dispersed in the 
synthesis medium [40]. 
 in an 
aqueous medium using trisodium citrate as a reducing agent. Special 
precautions were taken to avoid uncontrolled growth and aggregation 
of nanoparticles during preparation. The used weight per weight 
ratios of gold salt to citrate salt were 1:10, 1:20 and 1:30 [39]. 
Characterization of the prepared nanoparticles 
UV-Vis scanning of gold nanoparticles 
Ultraviolet-visible light absorption spectra of citrate-stabilized, and 
polymers coated gold nanoparticles were taken at room 
temperature using a double beam spectrophotometer (Shimadzu 
1601, Japan). Two ml solution of gold nanoparticles was placed in a 
quartz cuvette, and the spectrum of the solution was recorded [41]. 
Size and surface charge measurements by photon correlation 
spectroscopy (PCS) 
The size, size distributions and the zeta potentials of the synthesized 
gold nanoparticles were analyzed by PCS using a Zeta sizer ZS 90 
(Malvern, Instruments GmbH, England). 300 μl of GNPs were added 
to 3 ml of Millipore water immediately before measuring their size 
and zeta potential. The refractive index and the viscosity of 
dispersion medium (water) were used for the calculation of the 
results [42].  
Imaging of gold nanoparticles by Transmission Electron 
Microscopy (TEM) 
Ten μl of the nanoparticle samples will be dropped on graphite 
coated copper grids and dried at room temperature before taking 
the images by TEM (Zeiss EM 10 C/CR, Germany) [34]. 
Dispersion stability of nanoparticles 
To simulate the in vivo conditions, the dispersion stability of bare 
and coated GNPs in high ionic strength solutions (5M NaCl), bovine 
serum albumin (BSA, 200 μg/ml) and plasma (10% v/v) were 
applied using UV-Vis absorption spectroscopy [41]. 
Determination of nanoparticles concentration 
The concentration of GNPs in the prepared solution was calculated 
using inductively coupled plasma (ICP-OES) (Horiba Jobin Yvon, 
70P, S+S, Munich, Germany). Firstly, 1 ml of GNPs solution was 
digested to gold salt (Au+3
Preparation and characterization of the functionalized GNPs 
loaded with the growth factor  
) by mixing with 2 ml of aqua regia (HCl: 
HNO3, 3:1 volume ratio). Complete dissolution of GNPs was 
observed within half an hour after the addition of aqua regia to 
colloidal gold. The amount of gold salt in digested solution was 
analyzed by ICP-OES at emission wavelengths of 268 and 243 nm. 
The concentration was calculated based on the standard curve 
constructed by using different concentrations of auric chloride. The 
concentration was calculated based on a standard curve constructed 
by using different concentrations of auric chloride [34, 43]. 
Decorating the surface of GNPs with NH2




Preparation of IGF-I loaded CS-PEG-AlkSH-GNPs 
-PEG-SH or CS-PEG-AlkSH were added 
to GNP solution (5µg/ml) to ensure complete coating of the 
particles’ surface with polymers. The resulting mixture was shacked 
overnight in a horizontal shaker set to 200 rpm at room temperature 
to allow the exchange of citrate anions with the thiol group of the 
polymers on the particle’s surface. The excess unbound polymer was 
removed by four times ultra-filtration at 750 g [34]. 
The positive charge of GNPs coated with chitosan can adsorb the 
negatively charged growth factors, such as IGF-I, by electrostatic 
attraction. Growth factors were loaded to CS-PEG-AlkSH-GNPs in a 
concentration of 100 ng/ml. An excess amount of IGF-I was added to 
the nanoparticles, and the free unbound drug was removed by 
ultrafiltration.  
Determination of loading efficiency 
The loading efficiency (%) of IGF-I loaded CS-PEG-AlkSH-GNPs was 
carried by determining the difference in concentrations between the 
added IGF-I (100 ng/ml) and the concentration determined in the 
supernatant. Two ml of nanoparticles containing IGF-I were filtrated 
(14,000g, 30 min) and the IGF-I concentration in the filtrate was 
determined by using IGF-I ELISA (enzyme-linked immunoassays) 
kits (eBioscience, San Diego, CA, US) according to the manufacturer’s 
instructions. This experiment was repeated three times, and 
encapsulation efficiency (EE) was calculated by applying the 
following equation [44, 45]: 
LE = [(Concentration of the added IGF
− Concentration of IGF in the supernatant)
÷ (Concentration of the added IGF)] ∗ 100 
Characterization of IGF-I loaded CS-PEG-AlkSH-GNPs 
Nanoparticles loaded with IGF-I were characterized using UV-visible 
spectroscopy, particle size analysis, zeta potential measurements 
and the dispersion stability as mentioned earlier. 
In vitro release, profile and bioactivity of IGF-I from IGF-I 
loaded CS-PEG-AlkSH-GNPs using cell culture technique 
The in vitro release profile of IGF-I from CS-PEG-AlkSH-GNPs was 
determined using eppendorf tubes, each filled with 250 μl PBS buffer 
of pH 7.4, containing 1% w/v BSA. Three mg of IGF-I loaded CS-PEG-
AlkSH-GNPs were added to each eppendorf tube. The tubes were 
closed and incubated in a shaking water bath (100 rpm) at 37 °C. At 
different time intervals, a specific number of eppendorf tubes were 
collected and centrifuged for 5 min at 3,000 rpm, and the 
supernatants were collected for IGF-I determination using ELISA (R 
and D systems, France). The cumulative release percentage was 
calculated based on the total amount of IGF-I obtained from the 
loading efficiency experiment. 
The IGF-I released at different time intervals from CS-PEG-AlkSH-
GNPs were checked for their bioactivity using cell culture technique. 
Human breast carcinoma (MCF-7) cell line was obtained from the 
American Type Culture Collection (ATCC, Rockville, MD). The cells 
were grown on RPMI-1640 medium supplemented with 10% 
inactivated fetal calf serum and 50µg/ml gentamycin. The cells were 
maintained at 37 °C in a humidified atmosphere with 5% CO 2
For cell count assays, the cell lines were suspended in the medium at 
concentration 5x10
 and 
were sub-cultured two to three times a week.  
4 cell/well in Corning® 96-well tissue culture 
plates and then incubated for 24 h. Two compounds were tested; 
free IGF-I and IGF-I loaded CS-PEG-AlkSH-GNP. Each of the two 
compounds was added into 96-well plates (six replicates) to achieve 
eight concentrations for each compound. After incubating for two 
days, the numbers of viable cells were determined by the MTT test. 
El-Feky et al. 
Int J App Pharm, Vol 11, Issue 1, 2019, 174-185 
 
177 
Briefly, the media was removed from the 96 well plates and replaced 
with 100 µl of fresh culture RPMI-1640 medium without phenol red 
then 10 µl of the 12 mmol MTT stock solution (5 mg of MTT in 1 ml 
of PBS) to each well including the untreated controls. The 96 well 
plates were then incubated at 37 °C and 5% CO2
In vivo study 
 for 4 h. An 85 µl 
aliquot of the media was removed from the wells, and 50 µl of DMSO 
was added to each well and mixed thoroughly with the pipette and 
incubated at 37 °C for 10 min. Then, the optical density was 
measured at 590 nm with the microplate reader (SunRise, TECAN, 
Inc, USA) to determine the number of viable cells and the percentage 
of viability was calculated as [1-(ODt/ODc)]x100% where ODt is the 
mean optical density of wells treated with the tested sample and 
ODc is the mean optical density of untreated cells [46]. 
For the in vivo investigation two types of functionalized GNPs were 
prepared, IGF-I loaded CS-PEG-ALK-SH-GNP (see section 2.7.1) and 
CH3O-PEG-ALK-SH-GNP, the latter was prepared as per the scheme 
reported by Zayed and Tessmar in 2012 and by Khaled et al., in 2016 
[34, 41]. CH3
Animal Bio-distribution of control (CH
O-PEG-ALK-SH-GNP was used as a positive control 
functionalized GNPs to evaluate the true targeting power of CS 
ligand in vivo. 
3
(CS-PEG-ALK-SH-GNP) gold nanoparticles  
O-PEG-ALK-SH-GNP) and 
targeted  
The in vivo biodistribution experiments were carried out using male 
mice weighing between 50 and 60 g (provided by the animal house of 
Assiut University, Egypt). Animal ethical approval was obtained from 
Ethics Committee of the Faculty of Pharmacy, Al-Azhar University, Assiut 
(approval code pharmaceut02) and was carried out in accordance with 
the National Institutes of Health guide for the care and use of Laboratory 
animals (NIH Publications No. 8023, revised 1978) 
Three groups of animals were used; Group 1: negative control group and 
it was used for the toxicity study, Group 2: injected with 200 µl of the 
dispersions of the control CH3O-PEG-ALK-SH-GNP and Group 3: injected 
with 200 µl of the dispersions of the IGF-I loaded CS-PEG-ALK-SH-GNP. 
Group 2 and 3 were injected intravenously in the tail vein of each 
anesthetized mouse. The animals had free access to food and water ad 
libitum before and during the experiments. At specific time intervals of 
15 min, 1, 6 and 24 h after the injection of GNPs, four injected mice were 
sacrificed, and blood samples were withdrawn in heparin zed tubes, and 
the main organs of each mouse including liver, spleen, and kidneys were 
collected. Blood samples were stored at 6 °C while the organs were 
stored at-80 °C till further analysis. 
Digestion of collected organs 
Each of the collected organs was accurately weighed, homogenized 
and digested by aqua regia (concentrated HCl and concentrated 
HNO3
Pharmacokinetic investigation of control and targeting GNPs 
; (3:1 v/v)) for the determination of their gold content using 
inductively coupled plasma optical emission spectroscopy (ICP-
OES). The concentration of gold in each of the assessed tissues was 
calculated and expressed as percent of the initially injected dose per 
gram (% ID/g) [47]. 
The pharmacokinetic profile of both CH3O-PEG-ALK-SH-GNP and 
IGF-I loaded CS-PEG-ALK-SH-GNP was determined in two groups of 
experimental mice at 0.25, 0.5, 0.75, 1, 2, 6, 8, 15, 18 and 24 h post 
injection. The concentrations of gold in blood samples was 
calculated and expressed as percent of the initially injected dose per 
gram (% ID/g). The pharmacokinetic profiles covered the 
concentration at zero time (C0), the elimination rate constant (Ke), 
the half-life (t0.5), the volume of distribution (Vd
Toxicity study 
) and the clearance 
(Cl) of both systems. Analysis was done using WinNonlin software 
(Version 2.1; Pharsight, Mountain View, CA). 
Macroscopic examination 
Tissues of organs isolated from the three groups of mice were 
investigated comparatively for changes in size, color, and 
morphology. Mice were also monitored for behavioral changes.  
Haematology analysis 
The blood of negative control mice as well as after intravenous 
injection of both CH3
Clinical chemistry analysis 
O-PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-
ALK-SH-GNP was collected at 1, 6 and 18 and 24 h in heparin tubes 
for haematology indexes analysis. These included haemoglobin (Hb), 
total white (WBC) and red (RBC) blood cell counts, lymphocytes 
(Lph), monocytes (Mono), and granulocytes (GR) counts. 
The blood of negative control mice as well as after intravenous 
injection of both CH3
Statistical analysis  
O-PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-
ALK-SH-GNP was collected at 1, 6 and 18 and 24 h, then it was 
centrifuged at 5000 rpm for 10 min to separate the serum for 
analysis. Serum clinical chemistry indexes analyzed included 
creatine (CR), aspartate aminotransferase (AST), alanine amino-
transferase (ALT) and albumin (ALB). 
Results are expressed as mean±SD or mean ± SE of multiple 
independent experiments. One-way analysis of variance (ANOVA) 
test was used to compare results between groups. Significance was 
set at *p<0.05, and statistical analysis was performed using 
MINITAB (Version 16.0; Minitab, State College, Pennsylvania, USA) 
and SPSS (Version 17.0; SPSS, Cary, North Carolina, USA).  
RESULTS AND DISCUSSION 
Synthesis of amino poly (ethylene glycol)-undecyl mercaptane 
(NH2PEG2000C11H22
Alkanethiol PEG amine was synthesized according to the methods 
previously reported by Zayed and Tessmar, 2012 [34], Khaled et al., 
2016 [41] and Mohamed et al., 2016 [48] through the selective 
tosylation of one terminal hydroxyl group of PEG 2000 diol to 
produce mono-protected PEG (intermediate 3, fig. 1). The results of 
the 
SH)  
1H-NMR spectrum of this compound showed the following 
signals; [13]C-NMR (CDCl3) δ: 145, 133.24, 130.04, 128.21, 72.19, 
70.79, 69.39, 61.95, 21.87, (CDCl3 , δ in ppm): 7.79 (2H, d, J = 8 Hz), 
7.49 (2H, d, J = 8 Hz), 4.56 (1H, t, J = 5.4 Hz, OH), 4.11 (2H, t, J = 4.4 
Hz, CH2-SO2), 3.49 (128H, s, PEG backbone), 2.43 (3H, s, CH3). The 
spectrum of the final product (fig. 2) obtained after the treatment of 
intermediate (6) by HCl and sodium azide showed the following 
signals; (CDCl3) 3.5-3.9 (m, 180H, OCH2CH2), 3.45 (m, 2H,-OCH2-), 
2.8 (t,t, 2 H,-CH2NH2), 2.55 (tt, 2H,-CH2
Synthesis and characterization of renal targeting ligand and 
conjugation with amine PEG-thiol 
SH) and 1.7-1.2 (m, 18 H, the 
remaining protons of the alkanepart). 
The conversion of chitosan’s secondary hydroxyl groups into a 
carboxylic acid functional group was confirmed using FT-IR where 
the characteristic carbonyl (C=O) band appeared at 1742 cm-1[37]. 
FT-IR of chitosan conjugated polyethylene glycol was characterized 
by the bands at 3470, 3295, 1734 cm-1.1H-NMR (DMSO-d6) 11.58 (s, 
1H, CONH); 4.75 (m, 1H, CHCONH), 4,25 (m, 2H, CH-CH2O), 3.2-3.7 
(190H, m, PEG backbone and remaining protons of chitosan), 2.85 
(m, 2H, CH-NH2), 2,54 (m, 2H, CH2
Preparing GNPs by citrate reduction method 
SH), 2.25 (m, 1H, CH-CHCONH), 
1.10-1.70 (m, 20H, proton of alkyl skeleton).  
The addition of sodium citrate solution caused a gradual change in 
the color of the boiling auric chloride solution from pale yellow to 
deep red. The complete development of the deep red color was 
obtained after boiling the solution for 20 min. Obtained GNPs are 
recorded to be monodisperse spheres the size of which is 
determined by the concentration of the used citrate anions and the 
chosen reaction conditions.  
Characterization of the prepared nanoparticles 
UV-Vis scanning of GNPs 
The spectrum of prepared GNPs is characterized by strong 
absorbance in the visible region at about 520 nm due to surface 
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plasmon resonance. The aqueous dispersions of GNPs showed a 
surface plasmon resonance at 524 nm, which originates form 
oscillation of the surface electron of the particles upon exposure to 
light and agrees with the findings of Zayed and Tessmar [34]. The 
λmax of the spectrum does not differentiate between the different 
sizes of the particles, it only provides a rough estimation of the 
particles size range [34]. 
Size and surface charge measurements by PCS 
The hydrodynamic sizes and surface charges of the obtained GNPs 
are listed in table 1 and the size distribution is graphically presented 
in fig. 3. 
 
 
Fig. 2: 1H-NMR spectrum of amino poly (ethylene glycol) undecyl mercaptane (NH2-PEG2000C11H22
 
SH) 
Table 1: The size, PI and surface charges of naked and coated GNPs 
Gold/Citrate ratio Size* Polydispersity index (PI)  (nm) Surface charges 
1:10 47.6±1.82 0.384 -47.12 
1:20 27.8±1.34 0.5 -42.19 
1:30 22.5±0.65 0.416 -39.13 
Citrate stabilized GNPs (1:30) Size* Poly dispersity index (PI)  (nm) Surface Charges 
GNPs coated with NH2-PEG-AlkSH 27.8±2.45 0.430 -3.19 
GNPs coated with CS-PEG-AlkSH 28.5±1.93 0.425 5.5 
*(Results are expressed as mean±SD, n=3) 
 
 
Fig. 3: PCS showing the size distribution of different GNPs batches 
 
As shown from size determination (table 1), an inverse proportion 
between the concentration of reducing agent (sodium citrate) and 
the size of the produced particles was detected, i.e., as the 
concentration of sodium citrate increases, the size of GNPs 
decreases. This finding could be explained on the bases that a higher 
citrate/gold ratio produces more nuclei of AU ° and hence, a large 
proportion of auric salts is consumed in the formation of nuclei and 
in turn, will not be available for the excessive deposition on the 
surface of the formed nuclei instead, it will be distributed over a 
relatively larger number of nuclei leading to the formation of small 
GNPs. Also, when the amount of sodium citrate decreases, 
inadequate amount of citrate anions is available to fully cover the 
formed GNPs resulting on thermostatically unstable GNPs which will 
aggregate together to form larger particles [49].  
All the prepared batches showed a polydispersity index (PI) less 
than 0.7 which indicates that the size variation between the 
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nanoparticles are formed. The negative surface charge of the 
prepared particles is attributed to the adsorption of citrate anions 
on the particles’ surfaces [40, 48].  
Imaging of GNPs by TEM 
The TEM image of GNPs obtained by using 1:30 gold/citrate ratio is 
shown in fig. 4. GNPs showed mostly a spherical shape while few 
were polygonal. The size determined by TEM was found to be 
slightly smaller than the size determined by PCS. This observation 
might be due to that TEM determines the dense electron mass of the 
particles while PCS determines the hydrodynamic size of the 
particles i.e., the size of GNPs together with the moving adjoining 
layer of the water, adsorbed anions and/or coating polymers [34]. 
Dispersion stability of nanoparticles 
The effects of sodium chloride, BSA and plasma on the stability of the 
prepared nanoparticles are shown in fig. 5. High concentration of 
sodium chloride (5 M) induced rapid aggregation of GNPs as 
indicated by the change of color from wine red to blue and the 
disappearance of UV-Vis characteristic absorption peaks. This effect 
is due to the neutralization of surface charges of the particles which 
is considered the main reason for the dispersion stability. 
Neutralization of the surface charges might have resulted in reduced 
electrostatic repulsion between individual particles and 
consequently, the hydrophobic-hydrophobic interaction was 
expected to be the prominent force acting on nanoparticles. These 
conditions lead to aggregation of nanoparticles, size increase, change 
of color form wine red to blue and finally the disappearance of the 
UV-Vis characteristic absorption peaks. Similar effects were 
observed when aqueous citrate-coated GNPs solutions were mixed 
with BSA and plasma which could also be due to the masking of the 
negative charges present on the particle surface, similar results were 
recorded by Mohamed et al., and Shalkevich et al. [48, 51]. 
 
 




Fig. 5: Effect of sodium chloride, plasma, and BSA on the UV-Vis spectroscopy of citrate-stabilized GNPs 
 
 
Fig. 6: UV-Vis absorption spectra of citrate-stabilized (black line) and coated GNPs (green color) 
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Determination of nanoparticles concentration 
The concentration of gold in the different batches of the prepared 
GNPs was determined using ICP-OES. Results indicate that almost all 
of the added gold salt has been converted to GNPs which means that 
the reduction of auric chloride is about 100% completed by the 
sodium citrate method [51, 52].  
Preparation, characterization and loading efficiency of the 
functionalized GNPs loaded with the IGF-I  
Monodisperse red colored GNPs obtained by the citrate reduction of 
auric chloride solution were characterized by strong absorbance in 
the visible region of UV-Visible spectrum at about 520 nm due to the 
surface plasmon resonance after exposure to light as mentioned 
earlier, while, the polymer modified nanoparticles with synthesized 
polymers were characterized by surface plasmon resonance at 527 
nm as shown in fig. 6. 
The size, zeta potential, and polydispersity index (PI) of citrate-
stabilized and polymer-coated GNPs are shown in table 1. The size of 
citrate-stabilized GNPs was about 22 nm. While coating the 
nanoparticles with polymer resulted in an increase in the size by 
about 5 nm. This was previously reported by Sebak in 2018 where 
the author reported particle size enlargement comparing of 
PEGylated to non-PEGylated nanoparticles [50] 
The increase in size might be due to the attachment of the polymer 
molecules on the particles’ surfaces. All the prepared GNPs showed 
polydispersity indices less than 0.5 which indicate the narrow size 
distribution of the particles. The surface charge (zeta potential) of 
citrate-stabilized GNPs was found to be about-40 mV which might 
have resulted from the adsorption of citrate anions on the surfaces 
of the nanoparticles. Coating GNPs with amine terminated PEG lead 
to a decrease in the negative surface charge from-40 mV to about-3 
mV. Additionally, coating the GNPs with CS-PEG-AlkSH resulted in a 
shift of the surface charge form about-40 mV to about 5 mV. The 
change of zeta potential after coating with NHR2R-PEG-SH polymer and 
chitosan modified polymer might be due to the attachment of the 
polymer amine groups which were mostly protonated and became 
positively charged with the negative charges resulting from the 
citrate anions thus, causing a neutralization state. Attachment of the 
polymer to gold surface led to the replacement of some of the 
adsorbed citrate anions form the nanoparticles’ surface. This finding 
could be considered a strong evidence of the efficient coating of 
GNPs with the polymer [34].  
The loading efficiency of IGF-I on the surface of functionalized GNPs 
was found to be 61.5±2.37 %. 
 
 
Fig. 7: Effect of sodium chloride on the UV-Vis absorption spectra of, NHR2R-PEG-AlkSH coated GNPs (a), CS-PEG-AlkSH coated GNPs (b) and 
citrate stabilized (c) 
 
Effect of coating GNPs with polymer on the stability in biological 
media  
Citrate-stabilized GNPs are unstable in the presence of electrolyte and 
proteins as indicated by the large increase in its size and the 
disappearance of the characteristic surface plasmon resonance as 
shown in fig. 5 and 7. The instability of citrate-coated GNPs in the 
presence of electrolytes and protein could be attributed to the masking 
and the neutralization of the surface negative charges which were the 
main reason of the stability of citrate-stabilized GNPs. The polymeric 
coated GNPs were found not to be affected by the presence of 
electrolyte and proteins. This finding might be due to the stabilization 
of the polymeric coated nanoparticles sterically rather than by 
electrostatic repulsion. Sterically stabilized GNPs were reported to be 
the most suitable form of GNPs for biological application [34]. 
In vitro release profile of IGF-I from IGF-I loaded GNPs and 
released IGF-I bioactivity assessment using cell culture 
IGF-I release profile from functionalized GNPs was quantified in vitro 
by ELISA and showed a 58.2 % IGF-I release after 24 h (fig. 8). 
Human breast carcinoma (MCF-7) cell line was selected to assess the 
bioactivity of IGF-I loaded CS-PEG-AlkSH-GNPs because this type of 
cell line expresses much higher levels of insulin receptor substrate 
than other cell lines, and consequently, it is expected to be extremely 
sensitive to any change on the IGF-I concentrations giving more 
accurate and more measurable results [52, 53]. Cell culture results 
showed that there was no difference in cell count between the free 
IGF-I and IGF-I loaded CS-PEG-ALK-SH-GNP compounds. These 
results indicate that the release of IGF-I loaded on the surface of 
chitosan functionalized GNPs was not hindered and growth factor 
was desorbed and effectively passed into the cell culture medium 
inducing a biological effect in cell growth similar to that of free IGF-I 
[51]. In addition, the released IGF-I maintained a bioactivity 
equivalent to its released percentage as shown in fig. 8.  
Animal Bio-distribution of control and targeted gold 
nanoparticles 
The present study compared the in vivo distribution profiles of 
CHR3RO-PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-ALK-SH-GNP-after 
0.25, 1, 6 and 24 h as displayed in fig. 9 and 10. The bio distribution 
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profile of each of CH3
For CH
O-PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-
ALK-SH-GNP-IGF-I in experimental mice was evaluated based on the 
GNPs content present in the biological samples collected after IV 
administration. 
3O-PEG-ALK-SH-GNP, a peak concentration representing 
about 47% of the injected nanoparticles was observed in the blood 
in the first minutes after injection, while, other investigated organs 
including liver, spleen, and kidneys generally showed very low 
levels. Fig. 9 shows that after the high peaking of CH3O-PEG-ALK-SH-
GNP at 0.25 hr in the blood, it started to decrease gradually from the 
circulation and increase in other tissues with insignificantly higher 
concentrations reported in the liver 24 hr after injection. These 
findings may be attributed to the surface PEGylation of GNPs at the 
time of injection which might have caused the shielding of 
nanoparticles from being identified and uptaken by organs like the 
liver and the spleen which are the main organs concerned with the 
removal of colloids from the body. In addition, the negative charge of 
those nanoparticles might have contributed to impeding 
opsonization [54]. This supports that the small percentage of 
nanoparticles reported up to 6 hr after injection in the liver and 
spleen are mainly due to the hepatobiliary elimination rather than to 
the capture of particles by Kupffer cells. Whereas, the significant 
decrease in CH3
 
O-PEG-ALK-SH-GNP concentration in the blood and 
subsequent increase in the liver, spleen, and kidneys after 24 h 
might be due to the desorption and removal of PEG moieties away 
from the GNPs’ surfaces followed by opsonization of the non 
PEGylated GNPs (i.e. unspecific adsorption of negatively charged 
proteins) [55]. This phenomenon is expected to lead to a large 
increase in the particles’ size resulting in an increased uptake of the 
large nanoparticles by the reticuloendothelial system especially the 
liver and spleen [56, 57]. 
 
Fig. 8: Shows IGF-I cumulative release along 24 h and its comparable bioactivity (Results are expressed as mean±SE, n=3) 
 
 
Fig. 9: In vivo distribution of control GNPs (CH3
 
O-PEG-ALK-SH-GNP), (results are expressed as mean±SE, n=4) 
IGF-I loaded CS-PEG-ALK-SH-GNP showed a different in vivo 
distribution profile as shown in fig. 10. The concentration of IGF-I 
loaded CS-PEG-ALK-SH-GNP decreased significantly in the blood 
over time while increasing in the kidneys reaching maximum 
concentration of about 60% in 6 h time. Compared to CH3O-PEG-
ALK-SH-GNP, the concentration of IGF-I loaded CS-PEG-ALK-SH-GNP 
in the kidneys were higher at all-time intervals (fig. 10). The 
maximum concentration of IGF-I loaded CS-PEG-ALK-SH-GNP 
detected after 6 h in the kidney was found to be 60% vs 15 % for 
CH3
The maximum detected the concentration of CH
O-PEG-ALK-SH-GNP, (*P value = 0.039215) and it decreased to 
about 40% vs 15 %, respectively (p ≤0.0 5), after 24 h (fig. 10). The 
20% reduction in IGF-I loaded CS-PEG-ALK-SH-GNP level in the 
kidney between 6 and 24 h might be due to the renal clearance 
process [55]. The level of IGF-I loaded CS-PEG-ALK-SH-GNP in blood 
decreased gradually from 44.02 % at 0.25 h after injection to 
3.71±1.12 % at 24 h time. The high concentration of IGF-I loaded CS-
PEG-ALK-SH-GNP in kidneys relative to other organs after 6 h 
indicates that that the nanoparticles are mainly retained in the kidney 
which could be attributed to the presence of low molecular weight 
chitosan, as a specific renal targeting ligand, on the surface of GNPs.  
3
Studies on functionalized GNPs bio distribution have shown that 
these NPs exhibited longer circulation time in rats [59] and mice 
O-PEG-ALK-SH-
GNP in the kidneys was about 15% after 6 h and remained nearly 
constant during the full period of investigation (24 h) as shown in 
fig. 10. These results could be a good proof of the excellent renal 
targeting properties of IGF-I loaded CS-PEG-ALK-SH-GNP-IGF-I [60]. 
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[60] however, liver and spleen remained their preferential organs, 
whereas, other studies demonstrated that functionalization 
through the addition of ligands on the surface of PEG-coated GNPs 
could be employed as a targeting strategy to guide the NPs to a 
desired organ as capping confer some stealth capacity that leads to 
simultaneous reduction in their retention in the spleen and liver 
[61] which could clearly tailor the in vivo kinetics and bio-
distribution of GNPs. 
  
 
Fig. 10: In vivo distribution of IGF-I loaded CS-PEG-ALK-SH-GNP (Results are expressed as mean±SE, n=4) 
 
 
Fig. 11: Blood concentrations of CH3
 
Pharmacokinetic investigation of control and targeting gold 
nanoparticles 
O-PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-ALK-SH-GNP at different time intervals (results are 
expressed as mean±SE, n=4) 
The calculated pharmacokinetic parameters of both injected CH3O-
PEG-ALK-SH-GNP and IGF-I loaded CS-PEG-ALK-SH-GNP are shown 
in table 2. The blood concentrations of both CH3O-PEG-ALK-SH-GNP 
and IGF-I loaded CS-PEG-ALK-SH-GNP were examined over 24 h 
period after intravenous administration in mice veins. At all tested 
time points the blood concentration of CH3O-PEG-ALK-SH-GNP was 
found higher than the concentration of IGF-I loaded CS-PEG-ALK-SH-
GNP as indicated in fig. 11. In addition, a large Vd value was reported 
with IGF-I loaded CS-PEG-ALK-SH-GNP over CH3O-PEG-ALK-SH-GNP 
and beyond the normal body fluid volume of mice which entails that 
IGF-I loaded CS-PEG-ALK-SH-GNP accumulate in organ tissues, in 
our case, in the kidneys as discussed earlier. CH3
The elimination half-life of IGF-I loaded CS-PEG-ALK-SH-GNP-IGF-I 
was found higher than that of CH
O-PEG-ALK-SH-GNP 
showed prolonged circulation half-life reduced clearance, and 
reduced volume of distribution (table 2) which is consistent with the 
findings with Wang et al., 2015 which reported that GNPs with low 
tissue targeting abilities, shows the fore mentioned featured 
parameters [62].  
3O-PEG-ALK-SH-GNP, which is 
explained by the higher affinity and accumulation of IGF-I loaded CS-
PEG-ALK-SH-GNP-IGF-I in the kidneys and relatively rapid removal 
form the blood. In the study conducted by Choi et al., PEGylated 
GNPs of multiple different compositions manifested extended blood 
circulation, with a half-life (t1/2
 
) that spanned from 7 to 38 h [63]. 
Table 2: Pharmacokinetic parameters of control and targeted gold nanoparticles 
Parameter Control GNPs * Targeted GNPs 
Conc. at zero time (Co) 41.98401±3.12 27.25208±2.83 
Elimination rate constant, Ke (h-1 0.047808±0.00 ) 0.09962±0.01 
Half-life, t0.5 14.49552±0.23 (h) 6.956421±0.09 
Volume of distribution, Vd (ml) 2.381859±0.10 3.669445±0.31 
Clearance, Cl (ml/h) 0.113872±0.04 0.365551±0.02 
*Results are expressed as mean±SD, n=3, the liver, and spleen have always been the main reservoir sites for metallic nanoparticles through their 
removal from the circulation by the reticuloendothelial system (RES).  
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Macroscopic examination of the isolated liver, kidney and spleen 
tissues showed no changes in tissue size, color and morphology 
by any of the tested GNP formulations versus the negative 
control group (group 1) 24 h after intravenous administration. 
Also, no behavioral changes were reported in mice of all tested 
groups with no significant differences in total body weight and 
feeding pattern, as compared with control animals (data not 
shown).  
As shown in table 3, there was no significant difference (p>0.05) in 
blood haematology and in serum clinical chemistry indexes between 
the three groups of mice proving that the tested functionalized GNPs 
were not toxic after intravenous administration in mice [62]. In the 
study conducted by El-Sayed et al., in 2015, rats injected with 
pegylated gold nanorods in a dose of 0.9 mg/kg via intravenous and 
intramuscular routes showed mild symptoms of toxicity [64]. 
  
Table 3: Blood haematology and serum clinical chemistry of all mice groups 
Sample time Hb (g/dl) WBC (103 RBC (10/µl) 6 Lph (%) /µl) Mono (%) GR (%) 
Negative control 
1 h 14.2±1.11 6.06±0.73 4.56±0.32 2.30±0.20 0.28±0.00 4.00±0.04 
6 h 14.1±0.93 6.31±0.72 4.32±0.43 2.11±0.37 0.24±0.00 3.95±0.12 
18 h 14.1±1.24 6.40±0.25 4.33±0.25 2.54±0.74 0.24±0.00 3.87±0.09 
24 h 14.3±0.36 6.12±0.81 4.45±0.33 2.31±0.48 0.24±0.00 3.92±0.25 
 CH3O-PEG-ALK-SH-GNP 
1 h 14.2±1.28 7.11±1.01 5.01±0.00 2.89±0.74 0.35±0.02 3.76±0.21 
6 h 13.9±0.38 6.89±0.82 4.78± 2.60±0.27 0.39±0.01 3.86±0.11 
18 h 13.9±0.74 6.58±0.94 4.86± 2.86±0.73 0.36±0.01 3.83±0.00 
24 h 14.1±0.00 7.09±0.36 4.91± 2.79±0.92 0.37±0.00 3.79±0.46 
 CS-PEG-ALK-SH-GNP-IGF-I 
1 h 14.3±0.29 6.34±1.27 4.65± 2.11±0.22 0.31±0.03 3.91±0.04 
6 h 13.7±0.99 6.45±0.88 4.36±0.00 2.32±0.61 0.35±0.00 3.88±0.33 
18 h 13.5±1.82 6.84±0.47 4.51± 2.16±0.82 0.32±0.00 3.91±0.54 
24 h 13.4±1.09 6.41±0.73 4.77± 2.09±0.48 0.34±0.02 3.98±0.00 
Sample time CR (mg/dl) AST (Unit//l) ALT (Unit//l) ALB (g/dl) 
Negative control 
1 h 0.28±0.00 36.12±2.19 45.16±4.24 2.67±0.00 
6 h 0.25±0.00 36.11±2.03 43.12±3.21 2.95±0.45 
18 h 0.25±0.00 41.02±2.40 43.10±2.63 2.85±0.32 
24 h 0.26±0.00 38.14±4.02 50.10±3.23 2.38±0.77 
 CH3O-PEG-ALK-SH-GNP 
1 h 0.24±0.01 33.23±2.94 37.13±2.32 3.14±0.35 
6 h 0.22±0.01 34.29±3.58 39.02±2.50 3.25±0.00 
18 h 0.27±0.00 27.28±4.95 41.23±4.32 3.25±0.04 
24 h 0.24±0.00 31.02±2.49 44.96±4.02 3.16±0.07 
 CS-PEG-ALK-SH-GNP-IGF-I 
1 h 0.18±0.00 29.01±1.30 36.12±3.04 2.68±0.11 
6 h 0.15±0.00 29.45±2.10 42.19±3.94 2.69±0.00 
18 h 0.15±0.00 32.19±4.48 44.12±2.44 2.48±0.43 
24 h 0.16±0.00 30.28±3.42 39.92±3.29 2.59±0.25 
Results are expressed as mean±SD, n=3 
 
CONCLUSION 
Stable GNPs functionalized with chitosan have been successfully 
prepared and characterized. The surface functionalization of GNPs 
with chitosan performed dual duties; initially, it acted as a carrier for 
the growth factor through electrostatic adsorption of negatively 
charged IGF-I with the positively charged chitosan. Secondly, it acted 
as a targeting ligand to direct the whole system to be relatively 
accumulated in the kidney, through an active targeting mechanism. 
Based on the study results, IGF-I loaded CS-PEG-ALK-SH-GNP 
represented an efficient tool for the safe, targeted delivery of IGF-I 
and other biomolecules to the kidneys.  
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